Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Results from the randomized, double-blind phase of the phase 4 REMODEL trial indicate that dupilumab significantly improved esophageal distensibility in adults with active eosinophilic esophagitis (EoE) compared with placebo at 24 weeks.

The findings, which were presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, by Evan Dellon, MD, a professor of medicine and adjunct professor of epidemiology at the University of North Carolina School of Medicine in Chapel Hill, suggest that the IL-4/IL-13 pathway inhibitor not only addresses mucosal inflammation in EoE but also produces measurable improvements in a functional marker of fibrostenotic disease, a dimension of EoE pathology that has historically lacked dedicated therapeutic evidence.

“For patients who have eosinophilic esophagitis, if the disease remains untreated, it can progress to narrowing of the esophagus, more severe symptoms, such as food impaction, and the need for esophageal dilation,” Dellon said in a statement. “[Dupilumab] showed a potential to modify the course of eosinophilic esophagitis – by improving esophageal size at just 6 months – the magnitude of this improvement corresponded to the benefit that could be seen from an esophageal dilation procedure. It also reduced hallmark endoscopic and histologic signs of disease, which further strengthens the evidence that type 2 inflammation plays an important role in the biology of this disease. The ongoing study will allow us to learn the even longer-term impact of [dupilumab] on the scarring and narrowing of the esophagus in EoE.”

EoE affects an estimated 1 in 850 individuals in developed countries and is characterized by type 2 inflammatory infiltration of the esophageal mucosa that, when inadequately treated, can progress to subepithelial fibrosis, esophageal strictures, and narrowing sufficient to cause food impaction.

Despite the availability of dupilumab as an FDA-approved therapy for EoE since 2022 in patients 12 years and older, and extended in January 2024 to children as young as 1 year weighing at least 15 kg, prospective data directly assessing the drug's impact on esophageal remodeling and distensibility in a randomized, controlled design had been limited.

REMODEL Trial Design and Primary Endpoint

The REMODEL trial enrolled 69 adults with active EoE who were randomly assigned in a 2:1 ratio to dupilumab 300 mg once weekly subcutaneously (n = 46) or placebo (n = 23) for 24 weeks. Stratification was based on prior dilation history. Baseline demographic and disease characteristics were described as generally comparable across treatment groups.

The primary endpoint was the absolute change from baseline in the esophageal distensibility plateau (DP), measured using the endoluminal functional lumen imaging probe (EndoFLIP). The DP is defined as the narrowest fixed diameter, in millimeters, of the distal esophageal body in response to increasing volume and pressure. EndoFLIP quantifies esophageal compliance and has emerged as an objective tool for identifying fibrostenotic changes in EoE that may not be fully apparent on standard endoscopy or histology alone.

Hierarchical secondary endpoints included percent change from baseline in DP, followed by changes in the Endoscopic Reference Score (EREFS) and EoE Histologic Scoring System (EoEHSS) grade and stage scores at week 24. Safety was also assessed.

Distensibility and Structural Outcomes at Week 24

At 24 weeks, results showed dupilumab produced a statistically significant improvement in esophageal distensibility relative to placebo. The least squares mean (LSM) change from baseline in DP diameter was +1.28 mm (SE, 0.29) in the dupilumab group versus −0.01 mm (SE, 0.42) in the placebo group, yielding an LSM difference of 1.30 mm (95% CI, 0.31–2.29; 

 <.05). The LSM difference in percent change from baseline in DP also reached significance at 7.78% (95% CI, 1.13–14.43; 

A notable subgroup finding emerged among patients with abnormal baseline DP below 17 mm, a threshold generally considered indicative of meaningful fibrostenotic impairment. In this subset, the between-group difference was larger than in the overall population: dupilumab patients gained a mean of +1.76 mm while placebo patients declined by −0.49 mm (LSM difference, 2.25 mm; 95% CI, 0.75–3.75).

Improvements in endoscopic and histologic outcomes were also observed. The LSM difference in EREFS score favored dupilumab over placebo by −4.96 points (95% CI, −6.06 to −3.85; 

 <.0001). The EoEHSS grade and stage scores similarly improved: LSM differences were −0.71 (95% CI, −0.86 to −0.57; 

 <.0001) and −0.65 (95% CI, −0.80 to −0.51; 

Dellon ES, Carlson DA, Greuter T, et al. DUPILUMAB IMPROVES ESOPHAGEAL DISTENSIBILITY IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: 24-WEEK RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED REMODELING WITH DUPILUMAB IN EOSINOPHILIC ESOPHAGITIS LONG-TERM (REMODEL) TRIAL. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Regeneron. Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial. May 5, 2026. Accessed May 5, 2026. 

https://newsroom.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-demonstrates-improved-esophageal-function

Articles

Dupilumab demonstrated statistically significant improvement in esophageal distensibility at 24 weeks in adults with active eosinophilic esophagitis, providing randomized evidence of benefit on a functional marker of fibrostenotic remodeling. In REMODEL (n=69; 2:1 randomization), EndoFLIP distensibility plateau increased versus placebo, with larger effects in patients with baseline DP <17 mm. Parallel reductions were observed in endoscopic activity (EREFS) and histologic severity (EoEHSS grade and stage), supporting type 2 cytokine blockade across inflammatory and structural disease domains.

Phase 4 dupilumab data show improvements in esophageal distensibility and disease-related structural changes and inflammation in the esophagus in EoE.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

REMODEL: Dupilumab Improves Esophageal Distensibility in EoE at 24 Weeks

Stephanie Gold, MD, is an instructor of medicine at the Icahn School of Medicine at Mount Sinai and a gastroenterologist at the Mount Sinai Hospital.

Treating Obesity in IBD With GLP-1 Receptor Agonists

 is increasingly recognized as a modifiable risk factor in 

 (IBD), associated with poor medication response, higher surgical rates, and diminished quality of life. However, effective, IBD-specific weight management strategies have remained largely unstudied.

New prospective data from a dedicated IBD-metabolic clinic suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs), combined with structured lifestyle counseling, can deliver substantial weight loss and meaningful symptomatic benefit in this population, without compromising IBD disease control. The findings were presented by Stephanie Gold, MD, a gastroenterologist at the Icahn School of Medicine at Mount Sinai, at Digestive Disease Week (DDW) 2026 in Chicago, IL.

"Obesity really impacts IBD outcomes," Gold told 

. "Our patients who are overweight or have obesity respond poorly to medications, have increased surgical needs, and poor quality of life. It's super important that we're addressing it."

The analysis included 95 patients with IBD and overweight or obesity, defined as BMI ≥25 kg/m², seen during the first 12 months of a multidisciplinary IBD-Metabolic Clinic. All patients received structured lifestyle counseling, including a plating-method dietary strategy, daily walking, and twice-weekly resistance training.

Of the 95 patients, 50 (53%) additionally initiated a GLP-1RA based on standard eligibility criteria (BMI ≥27 kg/m² with comorbidity or BMI ≥30) and insurance or self-pay access. Weight, stool frequency and consistency, fatigue, and IBD-related complications were assessed at baseline and at 3, 6, 9, and 12 months. Of note, vibration-controlled transient elastography revealed hepatic steatosis in 72% of patients at baseline, underscoring the metabolic burden of this population.

Weight loss in the GLP-1RA group was notable and widened progressively over time. At 12 months, patients receiving GLP-1RA therapy achieved a median weight reduction of 20.9%, compared with a 3.0% gain in the lifestyle-only group (

<.01). Patients on GLP-1RAs were also significantly more likely to report improvements in stool frequency, stool consistency, and fatigue as early as 3 months. Rates of ER visits, hospitalizations, and changes in IBD therapy were similar between groups, with no severe adverse events recorded.

Gold highlighted constipation, a common GLP-1RA side effect in the general population, as an unexpected benefit in IBD patients with high baseline stool frequency.

"If they're having 4 or 5 loose stools per day, a little constipation is actually a nice benefit," she said.

Central to the program's success, Gold emphasized, is its multidisciplinary structure, bringing together a metabolic hepatologist, an IBD-trained dietitian, endobariatric and bariatric specialists, and endocrinology colleagues in a single clinical setting, reducing the delays and coordination challenges patients face when navigating multiple providers independently.

Looking ahead, Gold expressed hope that GLP-1RAs will become a routine part of IBD care, noting that gastroenterologists are often a patient's primary touchpoint with the healthcare system.

"We may be the only access point with the medical system for many of these patients," she said. "It's really important that we're identifying if they're overweight or obese and offering effective and safe strategies."

Editor's note: Gold reports no relevant disclosures.

Gold S, Tiao J, Collen A, et al. GLP-1RA Therapy Plus Lifestyle Counseling Significantly Improves Clinical and Patient-Reported Outcomes in Patients Living With IBD and Obesity. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Kaazan P, Seow W, Yong S, Heilbronn LK, Segal JP. The Impact of Obesity on Inflammatory Bowel Disease. Biomedicines. 2023;11(12):3256. Published 2023 Dec 8. doi:10.3390/biomedicines11123256

Videos

Stephanie Gold, MD, explains prospective IBD-Metabolic Clinic data show GLP-1 RAs are safe and effective for weight management in IBD, with added benefits for bowel function and fatigue.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Strategic Alliance Partnership

Adding GLP-1 RA Therapy to Lifestyle Counseling Drives Weight Loss, Improves Outcomes in IBD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

approvals and late-breaking clinical data that signal continued momentum in kidney disease therapeutics.

The Agency expanded treatment options across immune-mediated and rare kidney diseases, including a new subcutaneous formulation of anifrolumab (Saphnelo) for systemic lupus erythematosus and the landmark approval of sparsentan (Filspari) as the first indicated therapy for

 focal segmental glomerulosclerosis (FSGS)

Meanwhile, results from the phase 3 APPLAUSE-IgAN trial presented at the 

2026 demonstrated clinically meaningful slowing of kidney function decline with iptacopan (Fabhalta), reinforcing the growing role of targeted therapies in glomerular disease.

Alongside these advances, expert-driven discussions on APOL1-mediated kidney disease and emerging combination strategies, including atrasentan layered onto SGLT2 inhibition, underscored a field rapidly advancing toward precision medicine.

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data!

Anifrolumab (Saphnelo) Wins FDA Approval for Subcutaneous Self-Administration in SLE

On April 27, 2026, the FDA approved anifrolumab for once-weekly subcutaneous self-administration for use in adult patients with moderate to severe systemic lupus erythematosus receiving standard therapy/

The approval was based on results from a multicenter, randomized, double-blind, placebo-controlled phase 3 TULIP-SC trial evaluating subcutaneous anifrolumab versus placebo in 367 adults aged 18 to 70 years. According to AstraZeneca, subcutaneous anifrolumab achieved a statistically significant and clinically meaningful reduction in disease activity compared with placebo on this endpoint.

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

On April 13, 2026, the FDA granted full approval to sparsenten to treat FSGS. This decision signaled a historic milestone for the rare kidney disease as the first approved therapeutic option for a historically off-label, supportive-care-dominated disease area.

Supported by data from 2 of the largest head-to-head interventional studies in adult and pediatric patients with FSGS, the phase 3 

, sparsentan’s mechanism combines dual endothelin A and angiotensin II type 1 receptor blockade to address podocyte injury without immunosuppression.

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

APPLAUSE-IgAN: Iptacopan (Fabhalta) Exhibits 49.3% Slower eGFR Decline in IgAN Patients Than Placebo

Iptacopan demonstrated a 49.3% slower rate of estimated glomerular filtration rate (eGFR) decline compared to placebo. The final 2-year results from the phase 3 APPLAUSE-IgAN trial. were announced by Novartis and presented as late-breaking data at the 2026 WCN.

Additional findings included a 43% reduction in the likelihood of composite kidney failure events and 40.7% of iptacopan-treated patients achieving target proteinuria, compared with 23.7% in the placebo group.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

For the third annual APOL1-mediated kidney disease day, HCPLive put together a feature including perspectives from 5 experts in the nephrology field. Topics included the problem of misdiagnosis, unpredictable progression, and uneven access to genetic insight, while considering the emergence of targeted therapies.

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

5 Nephrology Headlines You Missed in April 2026

hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS,

discussed several concepts presented at WCN 2026, including the phase 2 ASSIST trial, which evaluated the efficacy and safety of atrasentan in combination with SGLT2 inhibitors.

April 2026 delivered meaningful inflection points in kidney therapeutics, spanning immune-mediated, rare, and complement-driven glomerular diseases. FDA action enabled once-weekly subcutaneous self-administration of anifrolumab for moderate-to-severe SLE, potentially broadening outpatient usability. Sparsentan received full approval as the first indicated treatment for FSGS, supported by DUPLEX and DUET and leveraging dual ETA/AT1 blockade without immunosuppression. Late-breaking APPLAUSE-IgAN results showed iptacopan slowed eGFR decline and reduced kidney-failure events, underscoring accelerating precision strategies.

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

FDA News

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

, in Las Vegas, Nevada, brought together a number of key clinicians to share updates and advancements in everything from obesity and diabetes to 

. Trials like CAHtalyst Adult and discussions on topics like GLP-1s in 

 took center stage over the 3-day meeting.

With all of the new data and key perspectives being shared throughout the conference, the editorial team at 

 has collected 5 of the most impactful headlines to come out of AACE 2026. Catch up on any major data you may have missed during the conference below:


Reemphasizing Nutrition and Diet in Managing Chronic Endocrine Disease, With Jeffrey Mechanick, MD


Jeffrey Mechanick, MD, medical director of the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital, discusses the importance of employing nutritional goals in managing obesity and preventing additional endocrine diseases. Mechanick highlights the interplay between the metabolic system and the exposome, noting that nutrition is far more than simply diet and exercise – and every aspect has an impact on endocrine health.


Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD


2-year data from the CAHtalyst Adult study have shown substantial and sustained reductions in glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) when treated with crinecerfont. In addition to these positive results, Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan, discusses the substantial retention observed throughout the open-label extension.


Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD


Although the risks of iodine deficiency are well-documented, excess iodine also poses substantial risk to the thyroid – and can be caused through unexpected sources, including common micronutrient supplements and iodized salt. To address this, Shashank Joshi, MD, a consultant endocrinologist at Lilavati Hospital and Joshi Clinic, highlights a narrow iodine window that clinicians should target, given the thyroid’s intolerance of extremes in either direction.


Beyond Insulin: Evaluating GLP-1 RAs as Adjunctive Therapy in Type 1 Diabetes, With Viral Shah, MD


Although T1D treatment is largely reliant on insulin therapy, a significant proportion of patients fail to achieve time in range >70%, driven in part by rising rates of obesity. To this end, Viral Shah, MD, a professor of medicine in the division of endocrinology & metabolism and director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic Diseases at Indiana University, discusses the potential of implementing GLP-1 medications in T1D. Their well-documented efficacy in reducing excess adiposity, coupled with their potentially beneficial effects for cardiovascular health, make them an attractive potential adjunct to existing insulin therapy.


Diabetes Dialogue: Nutrition, Medication, and Treatment in Obesity With Elizabeth Bauer, MD


In a special on-site episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, meet with Elizabeth Bauer, MD, to discuss her “Year in Review” presentation at AACE. AACE’s updated obesity algorithm, emerging obesity pharmacotherapies, and the management of disease and medication side effects take center stage as Bauer covers the full scope of obesity in both the clinical and patient setting.

AACE 2026 emphasized integrated endocrine care spanning nutrition, obesity therapeutics, thyroid micronutrient management, and adrenal and diabetes innovations. Nutrition was framed as a targeted metabolic intervention influenced by the exposome, extending beyond diet and exercise. In classic CAH, 2-year CAHtalyst Adult data supported sustained glucocorticoid dose reductions with crinecerfont alongside strong open-label extension retention. Thyroid discussions stressed a narrow therapeutic window for iodine, with both deficiency and excess—often supplement-driven—posing risk. GLP-1 receptor agonists were positioned as potential adjuncts in T1D amid obesity and suboptimal time-in-range.

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

AACE 2026 Recap: 5 Key Presentations to Know

Syed-Mohammed Jafri, MD, is a Gastroenterologist and Transplant Hepatologist at Henry Ford Hospital.

Reducing TPN Burden & Improving Quality of Life in Short Bowel Syndrome

Short bowel syndrome (SBS) remains a life-altering condition, often requiring lifelong reliance on parenteral support to maintain nutrition and hydration. While these therapies are lifesaving, new data presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, highlight a growing recognition among clinicians: the burden of total parenteral nutrition (TPN) extends far beyond clinical stabilization, with significant implications for safety, complications, and quality of life.

Patients with SBS dependent on parenteral support face substantial clinical and lifestyle challenges due to reduced intestinal function. TPN remains the cornerstone of management, but it is associated with a range of complications, including infections, thrombosis, and liver injury.

“We have been continuing to work with patients with short bowel syndrome now for over 15 years, and following these patients over time and really seeing the tough life that they lead,” Syed-Mohammed Jafri, MD, a gastroenterologist and transplant hepatologist at Henry Ford Hospital, told 

The data presented at DDW stemmed from a noninterventional, cross-sectional online survey conducted among HCPs in the US and Europe with ≥2 years of experience treating SBS patients and actively managing ≥1 patient. The survey assessed perceptions of TPN-related complications, clinical burden, and preferred outcome attributes for potential new therapies.

HCPs reported a high burden associated with TPN in patients with SBS dependent on parenteral support, with central line complications, fatigue, and decreased QoL being primary concerns. Reducing time on TPN was considered more impactful than volume reduction.

According to Jafri, the traditional focus on stabilization represents only the first phase of care, pointing to the need for a more comprehensive, long-term management strategy . While TPN can prevent malnutrition and stabilize electrolytes, it also introduces new risks that must be actively managed over time.

The study findings reinforce this perspective, showing that healthcare professionals prioritize minimizing complications and keeping patients out of the hospital. However, there is increasing awareness that treatment goals must extend beyond safety alone.

A central theme of the research is the importance of reducing the burden of TPN, particularly in terms of time. Nearly half of surveyed clinicians identified reducing the number of days per week on TPN as the most valuable outcome, followed by reducing hours per day. By comparison, fewer respondents prioritized reducing infusion volume.

This aligns closely with patient experiences. Many individuals require TPN infusions for up to 12 hours daily, limiting their ability to work, socialize, or leave home. As Jafri noted, patients often seek “a break” from therapy to regain a sense of normalcy in their daily lives .

Beyond quality of life, reducing time on TPN is also clinically beneficial. Fewer infusion hours and days may reduce exposure to central venous catheters, thereby lowering the risk of infections and thrombosis, 2 of the most serious complications identified in the study.

Implications for Clinical Practice and Future Research

These findings signal a shift in how clinicians approach SBS management. While maintaining stability and preventing hospitalizations remain critical, there is growing emphasis on balancing these goals with quality of life considerations. Actively pursuing strategies to wean patients from TPN when feasible is becoming an increasingly important aspect of care.

Looking ahead, there remains a need for innovative therapies that reduce dependence on parenteral support while maintaining nutritional adequacy. Advances in intestinal rehabilitation, improved delivery methods, and novel pharmacologic agents may all contribute to this goal.

Equally important is increasing awareness of SBS within the gastroenterology community. Early recognition and referral to specialized centers can help ensure patients receive comprehensive care tailored to both clinical and lifestyle needs.

Jafri SM, Harrison J, Kumpf V, et al. BURDEN OF TOTAL PARENTERAL NUTRITION FOR PATIENTS WITH SHORT BOWEL SYNDROME DEPENDENT ON PARENTERAL SUPPORT: HEALTHCARE PROFESSIONAL PERSPECTIVES ON RISKS, LIMITATIONS, AND TREATMENT PRIORITIES. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

New research underscores the risks and daily burden of TPN in SBS, with focus shifting toward reducing dependence and complications.

Time Off TPN Emerging as Key Goal in Short Bowel Syndrome Care, With Syed-Mohammed Jafri, MD

Noreen Galaria, MD, is a board-certified and fellowship-trained dermatologist based in the Washington, D.C. area with over 20 years of experience. She is the founder of Inner Glow Vitamins and practices at Galaria Plastic Surgery & Dermatology.

Podcasts

In this new Skin of Color Savvy podcast, Noreen Galeria, MD, discusses topics such as patient, misinformation, her career, and research on natural remedies.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Misinformation, Holistic Dermatology, and Skin of Color, With Noreen Galaria, MD

April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiomyopathy

Atherosclerotic Cardiovascular Disease

7 Cardiology Headlines You Missed in April 2026

Gil Melmed, MD, is affiliated with Cedars-Sinai Inflammatory Bowel Disease Center.

Gil Melmed, MD, breaks down real-world data showing risankizumab has the lowest switch rates in Crohn’s over 24 months, highlighting strong persistence vs other biologics.

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease

Anat Shoshani, PhD, professor at Reichman University and chief psychologist at Kai.ai.

Shoshani discusses RCT data showing AI reduces anxiety and improves well-being, with outcomes comparable to those of group therapy. 

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Conversational AI for Anxiety Matches Group Therapy Outcomes, With Anat Shoshani, PhD

In this segment from the April episode of The Medical Sisterhood podcast, the speakers discussed simple ways for physicians to get involved in community service without feeling overwhelmed.

How to Get Involved in Community Service in Dermatology, With Elizabeth Kiracofe, MD

Volixibat reduced cholestatic pruritus in phase 2b primary sclerosing cholangitis data, with diarrhea and liver test elevations reported.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Volixibat Improves Pruritus in Phase 2b PSC Trial, With GI and Liver Safety Signals

Ariann Chelli, LCSW, LCADC, MBA, is the clinical director at Desert Hope Treatment Center, an American Addiction Centers facility.

Without FDA-approved medications or standardized detox protocols, clinicians face unique challenges treating methamphetamine addiction.

Addiction

Addiction medicine condition center page, resources on the topics of medical news and expert insight into clinical addiction can be found. Content includes articles, interviews, videos, podcasts, and breaking news on addiction therapy research, treatment, and drug development.

Treating Methamphetamine Use Disorder Without FDA-Approved Medications

Joseph Murray, MD, is a gastroenterologist at Mayo Clinic.

Murray breaks down what gastroenterologists need to know about celiac disease diagnosis and management.

Confronting Unmet Needs in Celiac Disease, With Joseph Murray, MD

Marla Dubinsky, MD, is chief of the division of pediatric gastroenterology and nutrition and co-director of the Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children's Hospital, Icahn School of Medicine.

Marla Dubinsky, MD, explains LIBERTY post hoc data showing SC infliximab 240 mg recaptured clinical response within 8 weeks in CD and UC patients following a drug holiday.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Subcutaneous Infliximab Recaptures Disease Control After Treatment Interruption in IBD

Laurie Keefer, PhD, is a clinical health psychologist and professor of medicine at Icahn School of Medicine at Mount Sinai.

Laurie Keefer, PhD, makes the case for integrating mental health, social determinants, and brain-gut behavior therapies into routine GI care.

Latest News

REMODEL: Dupilumab Improves Esophageal Distensibility in EoE at 24 Weeks

Adding GLP-1 RA Therapy to Lifestyle Counseling Drives Weight Loss, Improves Outcomes in IBD

5 Nephrology Headlines You Missed in April 2026

AACE 2026 Recap: 5 Key Presentations to Know

Time Off TPN Emerging as Key Goal in Short Bowel Syndrome Care, With Syed-Mohammed Jafri, MD